Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma
European Journal of Cancer2011Vol. 47(14), pp. 2117–2127
Citations Over TimeTop 1% of 2011 papers
Masatoshi Kudo, Kazuho Imanaka, Nobuyuki Chida, Kohei Nakachi, Won Young Tak, Tadatoshi Takayama, Jung‐Hwan Yoon, Takeshi Hori, Hiromitsu Kumada, Norio Hayashi, Shuichi Kaneko, Hirohito Tsubouchi, Dong Jin Suh, Junji Furuse, Takuji Okusaka, Katsuaki Tanaka, Osamu Matsui, Michihiko Wada, Iku Yamaguchi, Toshio Ohya, Gerold Meinhardt, Kiwamu Okita
Related Papers
- → High FLT3 Levels May Predict Sorafenib Benefit in Hepatocellular Carcinoma(2020)21 cited
- → Prognostic factors in patients with hepatocellular carcinoma treated with Sorafenib(2011)4 cited
- → Significance of PIVKA-II in sorafenib therapy for advanced hepatocellular carcinoma(2010)1 cited
- [Advanced hepatocellular carcinoma: importance of clinical trials].(2015)
- → Heat Shock Protein 27 Expression Levels are associated with the Sensitivity of Hepatocellular Carcinoma Cells to Sorafenib(2022)